公开(公告)号：EP1806147B1

公开(公告)日：2014-04-30

申请号：EP05795461.2

申请日：2005-10-20

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： ODANI, Tomoyuki, ONO PHARMACEUTICAL CO., LTD. ,  TADA, Hideaki, ONO PHARMACEUTICAL CO., LTD. ,  YAMADA, Kimiho

IPC分类号： A61K45/00 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/395 ,  A61K48/00 ,  A61P29/00 ,  A61P31/04 ,  A61P35/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P37/08

CPC分类号： C07K14/47 ,  A61K31/7088 ,  A61K38/1709 ,  A61K38/1774 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K2319/30 ,  G01N33/6854 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/466

摘要： The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and the antagonist of BIRI has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.

公开(公告)号：EP1806147A1

公开(公告)日：2007-07-11

申请号：EP05795461.2

申请日：2005-10-20

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： ODANI, Tomoyuki, ONO PHARMACEUTICAL CO., LTD. ,  TADA, Hideaki, ONO PHARMACEUTICAL CO., LTD. ,  MOROE, Kimiho, ONO PHARMACEUTICAL CO., LTD.

IPC分类号： A61K45/00 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/395 ,  A61K48/00 ,  A61P29/00 ,  A61P31/04 ,  A61P35/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P37/08

CPC分类号： C07K14/47 ,  A61K31/7088 ,  A61K38/1709 ,  A61K38/1774 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K2319/30 ,  G01N33/6854 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/466

摘要： The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides.
BIR1 functions as an immunosuppressive receptor, and the antagonist of BIRI has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.